​In the interest of full transparency, Dr. Aguirre reports the following financial disclosures:
 
Consulting: Anji Pharmaceuticals, Affini-T Therapeutics, Arrakis Therapeutics, AstraZeneca, Boehringer Ingelheim, Kestrel Therapeutics, Merck & Co., Inc., Mirati Therapeutics, Nimbus Therapeutics, Oncorus, Inc., Plexium, Quanta Therapeutics, Reactive Biosciences, Revolution Medicines, Riva Therapeutics, Servier Pharmaceuticals, Syros Pharmaceuticals, Third Rock Ventures, T-knife Therapeutics, and Ventus Therapeutics

Equity: Riva Therapeutics
 
Research Funding: Bristol Myers Squibb, Deerfield, Inc., Eli Lilly, Mirati Therapeutics, Novartis, Novo Ventures, Revolution Medicines, and Syros Pharmaceuticals

Updated: September 1, 2023